 Shares of Entrada Therapeutics Inc. TRDA, 3.20 rallied 15 in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, 1.85 that aims to develop treatments for myotonic dystrophy type 1, a genetic disorder that causes progressive muscle weakness. The collaboration includes Entradas ENTR-701, which is currently in preclinical studies. 